Boundless Bio, Inc. (BOLD)

Boundless Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-65.69	-65.36	-49.43	-45.9	-25.21
Depreciation & Amortization	1.14	1.09	0.96	0.94	0.68
Loss (Gain) From Sale of Investments	-4.9	-5.06	-3.3	0.5	0.54
Stock-Based Compensation	7.99	7.52	3.34	2.29	1.16
Other Operating Activities	2.89	2.65	2.39	1.7	0.42
Change in Accounts Payable	-1.1	0.78	1.66	1.91	1.22
Change in Other Net Operating Assets	0.08	-2.45	-2.46	-1.05	-2.06
Operating Cash Flow	-59.6	-60.84	-46.86	-39.6	-23.25
Capital Expenditures	-2.51	-2.54	-0.63	-1.07	-2.03
Investment in Securities	-38.67	-23.57	-37.63	17.2	-57.25
Investing Cash Flow	-41.18	-26.1	-38.26	16.13	-59.29
Issuance of Common Stock	93.11	93.17	0.18	0.13	0.21
Other Financing Activities	-2.37	-3.35	-1.96	-	-
Financing Cash Flow	90.75	89.82	97.9	0.13	105.53
Net Cash Flow	-10.03	2.88	12.78	-23.34	22.99
Free Cash Flow	-62.11	-63.38	-47.49	-40.66	-25.28
Free Cash Flow Per Share	-2.79	-3.73	-39.05	-37.04	-29.38
Levered Free Cash Flow	-37.34	-37.58	-30.95	-24.76	-
Unlevered Free Cash Flow	-37.34	-37.58	-30.95	-24.76	-
Change in Net Working Capital	-2.13	-2.15	0.36	-2.12	-

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q